NEW YORK, Sept. 19, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against American Renal Associates Holdings, Inc. (“American Renal Associates” or the “Company”) (NYSE:ARA) and certain of its officers. The class action is on behalf of a class consisting of all persons or entities who purchased American Renal Associates securities: (1) pursuant and/or traceable to American Renal’s Initial Public Offering on or about April 21, 2016 (the “IPO”); and/or (2) from April 21, 2016 through August 18, 2016, inclusive (the “Class Period”).
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) American Renal was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for American Renal’s dialysis services; (2) the foregoing scheme was in violation of federal and state laws; and (3) as a result, American Renal’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/ara or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in American Renal Associates you have until October 31, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Apple Turns 50: From Garage Startup to AI Crossroads
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 



